These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35978659)

  • 41. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
    Dongoran RA; Tu FC; Liu CH
    Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.
    Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W
    Front Nutr; 2022; 9():906511. PubMed ID: 35782947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities.
    Pan J; Li Q; Sun Y; Gu Y; Ding Y; Pang N; Zhou Y; Pei L; Gao M; Ma S; Xiao Y; Wu F; Hu D; Chen YM; Yang L
    Diabetes Metab Syndr Obes; 2023; 16():187-200. PubMed ID: 36760590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes.
    Mastromauro C; Polidori N; Giannini C
    Curr Opin Pediatr; 2022 Aug; 34(4):414-422. PubMed ID: 35836399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
    Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
    Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies.
    Al Hashmi K; Giglio RV; Pantea Stoian A; Patti AM; Al Waili K; Al Rasadi K; Ciaccio M; Rizzo M
    Front Nutr; 2024; 11():1355732. PubMed ID: 38567250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.
    Carnagarin R; Tan K; Adams L; Matthews VB; Kiuchi MG; Marisol Lugo Gavidia L; Lambert GW; Lambert EA; Herat LY; Schlaich MP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.
    Lin YC; Wu CC; Ni YH
    Front Pediatr; 2020; 8():603654. PubMed ID: 33363067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease.
    Han AL
    Diabetol Metab Syndr; 2022 Mar; 14(1):44. PubMed ID: 35317824
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016.
    Zhang HJ; Wang YY; Chen C; Lu YL; Wang NJ
    Chin Med J (Engl); 2021 Jun; 134(13):1593-1601. PubMed ID: 34091530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks.
    Barber TM; Kabisch S; Pfeiffer AFH; Weickert MO
    Metabolites; 2023 Jun; 13(6):. PubMed ID: 37367914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut microbiota in MAFLD: therapeutic and diagnostic implications.
    Alghamdi W; Mosli M; Alqahtani SA
    Ther Adv Endocrinol Metab; 2024; 15():20420188241242937. PubMed ID: 38628492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study.
    Liu HH; Cao YX; Jin JL; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Dong Q; Zheng MH; Li JJ
    Hepatol Int; 2021 Dec; 15(6):1337-1346. PubMed ID: 34626331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.
    Xian YX; Weng JP; Xu F
    Chin Med J (Engl); 2020 Dec; 134(1):8-19. PubMed ID: 33323806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.
    Hegarty R; Kyrana E; Fitzpatrick E; Dhawan A
    Ther Adv Endocrinol Metab; 2023; 14():20420188231160388. PubMed ID: 36968656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
    Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
    Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.